Methods-writing week compresses many decisions into a short period: which materials to cite, which acceptance criteria to set, which checks belong in the method and which belong in the batch record. An HPLC purity figure often arrives early in that process, usually as a single percentage on a certificate or catalogue page. It looks decisive. It is not. For a research group working with lyophilised peptides and other research-use-only materials, the figure is best read as a chromatographic observation tied to a particular method, detector wavelength, integration routine and sample preparation. It can support a suitability decision, but it cannot carry the whole argument. All materials discussed here are for controlled laboratory and analytical research only; they are not for human or veterinary use, consumption, administration or clinical application.
What an HPLC Purity Percentage Actually Confirms
An HPLC purity figure usually reports the area of the main peak as a proportion of total integrated peak area in a defined chromatographic run. That makes it a relative measure, not an absolute measure of chemical purity. It confirms that, under the stated method, one peak dominated the UV trace at the chosen detection wavelength. It does not confirm that the peak is the intended peptide, that the sequence is correct, that the counterion is appropriate, or that the material is free from water, residual solvents, excipients or inorganic contaminants. A certificate may pair the purity result with identity testing and other data, but the percentage on its own should not be read as a complete characterisation. Purity is method-dependent: a change in column chemistry, gradient, mobile phase, wavelength or integration threshold can change the number without changing the material.
During methods writing, this distinction matters because the purity figure often gets copied into a materials table as though it were a fixed property. A more defensible approach is to record the figure alongside its context: the certificate reference, the batch identifier, the analytical method named on the CoA and the label reference printed on the vial. Research Sciences publishes that batch-level CoAs are supplied for supported products and that labels use a SKU-and-expiry reference format, for example BPC10-03/27; that reference should be quoted when documentation is queried. The figure also does not establish that the material is suitable for a particular in-vitro assay. Solubility in the chosen diluent, behaviour on reconstitution, adsorption to plasticware and stability during freeze–thaw are separate laboratory questions. Where a batch is sourced through a UK supplier such as Uk peptides, the accompanying CoA and label should travel with the material into the method record. The percentage is a starting signal, not a substitute for the batch document or the group’s own suitability checks.
What HPLC Purity Figures Do Not Resolve Before You Write the Method
Purity figures are often asked to answer questions they were never designed to answer. They do not resolve identity in the sense of sequence confirmation, and they do not demonstrate that minor peaks are irrelevant to a specific assay. A small impurity that is chromatographically resolved may matter far less than an unresolved species that co-elutes with the main peak, and area-percentage purity cannot distinguish between those cases without orthogonal data. They also do not resolve the excipient profile. Research Sciences states in its FAQs that its peptides contain trace amounts of mannitol, an excipient used for lyophilisation and storage handling; that is a formulation fact that belongs in the method notes, not something an HPLC purity percentage can replace. Nor does the percentage establish heavy-metal content, endotoxin status, bioburden, water content or residual solvent levels. The shop describes a testing framework covering purity, identity, heavy metals and endotoxin evaluation for supported products, but a researcher should open the specific batch CoA and confirm which tests apply to that batch.
The comparability trap
There is also a comparability problem. A purity figure does not confirm that two deliveries share a production lot, even when the same Internal Test Reference appears on restocked items. Research Sciences says an ITR links to associated sample testing reports but does not confirm that separate deliveries come from the same production lot or have had separate independent testing. Vial cap colour and other packaging can vary and are not indicators of identity, analytical quality or manufacturing origin. The current homepage lists published lines such as “≥99% Verified Purity”, “UK Research Materials Over 99.1% Purity” and “CoAs Janoshik Analytical Reports”; those are the shop’s current published wording at the time of writing and should be reconfirmed on the live page and against the batch CoA. They are not a substitute for the group’s own acceptance criteria. A purity figure also says nothing about storage history, repeated freeze–thaw cycles or whether the material has been handled within a controlled in-vitro workflow. These are method-design issues, not catalogue issues, and they need to be written into the protocol rather than inferred from a percentage.
Putting Purity Data in Its Proper Place in the Methods Section
In a methods-writing week, the practical question is not “is this purity figure high enough?” but “what role is this figure playing in the method?” Purity data works best as a screening and documentation aid: it helps a group decide whether a batch is worth progressing to full suitability testing, and it gives the method record a traceable certificate reference. It should not replace system suitability checks, blank injections, control samples, linearity, precision, accuracy or specificity testing for the assay itself. For an in-vitro laboratory workflow, the method should state the diluent, the target concentration for the assay, the vessel type, the storage conditions before and after reconstitution, and the freeze–thaw limits the group will accept. Research Sciences’ published handling guidance says lyophilised peptides should be stored at –20°C or below, sealed with desiccant and protected from moisture, heat and light, and that reconstituted material is less stable and should be stored at 2–8°C for short-term laboratory use; those are handling recommendations to verify against the batch documentation and the group’s own COSHH assessment.
Documentation and handling checks
The documentation trail should be just as explicit. Record the batch CoA reference, the vial label reference, the date received, the storage location and any internal aliquoting step. If the CoA includes identity data alongside HPLC purity, note the method and the acceptance criterion used, but do not silently convert the supplier’s criterion into the group’s own. Where the shop’s published terms say orders are dispatched the next working day and shipped via Royal Mail Tracked 24 with delivery estimates rather than guarantees, that is fulfilment information, not analytical information; it should not influence how the purity figure is interpreted. Similarly, the shop’s published “24hr UK Delivery” line is a marketing statement to reconfirm at checkout, not a certificate claim. For materials management, the important point is that purity figures belong in a document-control chain, not in isolation. A percentage can open the door to a batch; the CoA, label and in-house suitability data decide whether the batch stays in the method. All such materials remain research-use-only and are not for human or veterinary use.
Amsterdam blockchain auditor roaming Ho Chi Minh City on an electric scooter. Bianca deciphers DeFi scams, Vietnamese street-noodle economics, and Dutch cycling infrastructure hacks. She collects ceramic lucky cats and plays lo-fi sax over Bluetooth speakers at parks.